科伦药业：子公司在2025年欧洲肿瘤内科学会大会上公布多项创新药物研究成果

Core Viewpoint - The announcement by Kelun Pharmaceutical regarding the presentation of multiple clinical research results at the 2025 European Society for Medical Oncology (ESMO) conference highlights the company's advancements in targeted antibody-drug conjugates (ADCs) [1] Group 1: Clinical Research Results - Kelun Pharmaceutical's subsidiary, Sichuan Kelun Biotech Co., Ltd., presented data on several ADCs, including sac-TMT targeting TROP2, A166 targeting HER2, and SKB315 targeting Claudin18.2 [1]